KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Equity Average (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Equity Average for 18 consecutive years, with $31.3 billion as the latest value for Q1 2026.

  • For Q1 2026, Equity Average rose 6.71% year-over-year to $31.3 billion; the TTM value through Mar 2026 reached $31.3 billion, up 6.71%, while the annual FY2025 figure was $30.3 billion, 9.55% up from the prior year.
  • Equity Average hit $31.3 billion in Q1 2026 for Regeneron Pharmaceuticals, up from $31.1 billion in the prior quarter.
  • Across five years, Equity Average topped out at $31.3 billion in Q1 2026 and bottomed at $19.3 billion in Q1 2022.
  • Average Equity Average over 5 years is $26.1 billion, with a median of $26.5 billion recorded in 2024.
  • Year-over-year, Equity Average surged 68.17% in 2022 and then rose 5.85% in 2025.
  • Regeneron Pharmaceuticals' Equity Average stood at $22.1 billion in 2022, then rose by 15.36% to $25.4 billion in 2023, then rose by 15.33% to $29.3 billion in 2024, then increased by 6.02% to $31.1 billion in 2025, then increased by 0.75% to $31.3 billion in 2026.
  • According to Business Quant data, Equity Average over the past three periods came in at $31.3 billion, $31.1 billion, and $30.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.